Lightlake Therapeutics, Inc. Acquires a Patent With the Potential to Establish a New Treatment Paradigm to Terminate …

More info…
LONDON — Lightlake Therapeutics Inc has acquired US Patent 5,587,381, entitled: ‘Method for terminating methadone maintenance through extinction of the opiate-taking responses’, using an opioid antagonist as treatment.

detox opiate